Meet us next:   ELRIG UK 2025 – 20 March  ●  IBD Innovate 2025 – 9-10 April  ●  NIH Spring Vendor Exhibit 2025 – 24 April  ●  AACR Annual Meeting 2025 – 27-30 April  ●  ISCT Conference 2025 – 7-9 May  ●  more on our events calendar

Recombinant human IL-7 protein

QK095

Brand: Qkine

Interleukin-7 (IL-7) is a vital cytokine essential for immune system regulation, particularly in the development and maintenance of T cells, playing a crucial role in both adaptive and innate immune responses. Recombinant human IL-7 stimulates the development of lymphoid progenitor cells.

Qkine has optimised the IL-7 manufacture process to produce a highly bioactive protein with excellent lot-to-lot consistency for enhanced experimental reproducibility.

IL-7 is a highly pure 17.5 kDa monomer, animal origin-free (AOF) and carrier-protein-free (CF).

Qkine 3-for-2 product campaign

Currency: 

Product name Catalog number Pack size Price Price (USD) Price (GBP) Price (EUR)
Recombinant human IL-7 protein, 25 µg QK095-0025 25 µg (select above) $ 280.00 £ 205.00 € 240.00
Recombinant human IL-7 protein, 50 µg QK095-0050 50 µg (select above) $ 410.00 £ 305.00 € 357.00
Recombinant human IL-7 protein, 100 µg QK095-0100 100 µg (select above) $ 620.00 £ 455.00 € 532.00
Recombinant human IL-7 protein, 500 µg QK095-0500 500 µg (select above) $ 2,500.00 £ 1,840.00 € 2,150.00
Recombinant human IL-7 , 1000 µg QK095-1000 1000 µg (select above) $ 3,950.00 £ 2,900.00 € 3,388.00

Note: prices shown do not include shipping and handling charges.

Qkine company name and logo are the property of Qkine Ltd. UK.

Alternative protein names
Interleukin 7
Species reactivity

human

species similarity:
mouse – 56%
rat – 57%
porcine – 69%
bovine – 71%

Frequently used together with:

Summary

  • High purity human IL-7 protein (Uniprot number: P13232)
  • >98%, by SDS-PAGE quantitative densitometry
  • Source: Expressed in E. coli
  • 17.5 kDa monomer
  • Animal origin-free (AOF) and carrier protein-free
  • Manufactured in Cambridge, UK
  • Lyophilized from Acetonitrile and Trifluoroacetic acid
  • Resuspend in water at >100 µg/mL, prepare single-use aliquots, add carrier protein if desired, and store frozen at -20°C or -80°C
Handling and Storage FAQ

Featured applications

  • Development, survival, and function of T cells
  • Maintenance of naive and memory T cells, crucial for immune surveillance and long-term immune memory
  • Development and formation of B cells
  • Development and formation of NK cells
  • Enhancement of immune responses in diseases like cancer, HIV, and during immune reconstitution following bone marrow transplantation
  • Development of regenerative medicine and vaccines

Bioactivity

Recombinant IL-7 activity was determined using proliferation of mouse-derived B lymphocyte cell line 2E8. Cells were treated in duplicate with a serial dilution of IL-7 for 65 hours. Cell viability was measured using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega). Data from Qk095 lot 204669. EC50 = 0.40 ng/ml (23 pM).

Purity

Recombinant IL-7 migrates as a major band at approximately 17.5 kDa (monomer) in reduced (R) and non-reduced (NR) conditions. No contaminating protein bands are present. The purified recombinant protein (3 µg) was resolved using 15% w/v SDS-PAGE in reduced (+β-mercaptoethanol, R) and non-reduced (NR) conditions and stained with Coomassie Brilliant Blue R250. Data from Qk095 lot #204669.

Further quality assays

  • Mass spectrometry, single species with the expected mass
  • Endotoxin: <0.005 EU/μg protein (below the level of detection)
  • Recovery from stock vial: >95%

Qkine IL-7 is as biologically active as a comparable alternative supplier IL-7 protein

Recombinant IL-7 activity was determined using proliferation of the mouse-derived B lymphocyte cell line 2E8. Cells were treated in duplicate with a serial dilution of Qkine IL-7 (Qk095, green) for 65 hours. Cell viability was measured using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega). Assay was performed by SBH Sciences using their standard (black) for comparison. Data from Qk095 lot #204669.

Protein background

IL-7 is a non-glycosylated protein with a molecular weight of about 17.5 kDa. It features four alpha-helices that facilitate its interaction with the IL-7 receptor (IL-7R), a heterodimer consisting of the IL-7Rα chain (CD127) and the common gamma chain (γc, CD132). This binding initiates signaling through the JAK-STAT pathway, particularly involving STAT5 phosphorylation, which promotes T cell survival, proliferation, and differentiation [1].

IL-7 is essential for the survival and homeostasis of T cells, supporting the development of thymocytes in the thymus and maintaining naive and memory T cells in the periphery, thus ensuring effective immune surveillance and long-term memory [2]. IL-7 influences B cell development and plays a role, though less prominently, in the development of natural killer (NK) cells [2,3].

IL-7 is extensively studied for its potential in cancer immunotherapy, where it enhances immune responses, particularly in promoting T cell recovery following chemotherapy or radiation, and in combination with checkpoint inhibitors [4]. In HIV and other chronic infections, IL-7 is explored for its ability to restore immune function by increasing CD4+ T cell counts and reducing immune exhaustion, potentially improving the effectiveness of existing therapies [2]. IL-7 also plays a key role in bone marrow transplantation, where it accelerates T cell recovery, reduces immune vulnerability, and is studied for its potential to mitigate graft-versus-host disease (GVHD) [4,5].

In autoimmune diseases like multiple sclerosis and rheumatoid arthritis, IL-7 is a target for controlling autoreactive T cell survival and proliferation, offering new therapeutic approaches [5]. IL-7 is investigated as a vaccine adjuvant, particularly in vaccines requiring strong T cell responses, and in regenerative medicine, where its role in expanding T cells and hematopoietic stem cells is harnessed to enhance the efficacy of immune system regeneration therapies [4,5,6].

Background references

  1. McElroy, C.A., Holland, P.J., Zhao, P., et al. Structural reorganization of the interleukin-7 signaling complex. Proc. Natl Acad. Sci. USA 109, 2503–2508 (2012). doi: 10.1073/pnas.1116582109.
  2. Barata, J.T., Silva, A., Brandão, J.G., et al. IL-7 and IL-7R in immune homeostasis and cancer. Trends Immunol. 40, 580–594 (2019). doi: 10.3390/ijms231810412
  3. Mazzucchelli, R. & Durum, S.K. IL-7 receptor signaling in T cell development and homeostasis. Front. Immunol. 8, 531 (2017).
  4. Pellegrini, M., Calzascia, T., Elford, A.R., et al. The expanding role of IL-7 in immunotherapy for cancer. Clin. Cancer Res. 25, 5150–5159 (2019).
  5. Sportès, C., Hakim, F.T., Memon, S.A., et al. IL-7 therapy in immune reconstitution: A focus on stem cells and T cells. Blood 127, 6–20 (2016).
  6. Sereti, I., Dunham, R.M., Spritzler, J., et al. Interleukin-7 in chronic viral infections and beyond. Annu. Rev. Med. 68, 627–641 (2017).